Market open
Atea/$AVIR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Atea
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Ticker
$AVIR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
75
Website
Atea Metrics
BasicAdvanced
$265M
-
-$2.07
0.17
-
Price and volume
Market cap
$265M
Beta
0.17
52-week high
$4.60
52-week low
$2.75
Average daily volume
379K
Financial strength
Current ratio
19.329
Quick ratio
19.167
Long term debt to equity
0.228
Total debt to equity
0.4
Management effectiveness
Return on assets (TTM)
-14.25%
Return on equity (TTM)
-33.45%
Valuation
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-2.078
Growth
Earnings per share change (TTM)
31.57%
3-year earnings per share growth (CAGR)
88.08%
What the Analysts think about Atea
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Atea stock.
Atea Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Atea Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Atea News
AllArticlesVideos
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
GlobeNewsWire·1 day ago
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 months ago
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Atea stock?
Atea (AVIR) has a market cap of $265M as of February 25, 2025.
What is the P/E ratio for Atea stock?
The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of February 25, 2025.
Does Atea stock pay dividends?
No, Atea (AVIR) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Atea dividend payment date?
Atea (AVIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Atea?
Atea (AVIR) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.